Screener
Summit Therapeutics SMMT CapEx
CapEx at other companies
Other financials
Where this comes from
Reported directly by Summit Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.
The source filing: Summit Therapeutics’s 10-Q, filed April 30, 2026.
- Filed
- Apr 30, 2026, 5:00 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001599298-26-000039
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Cash flows from investing activities: | ||
| Maturities and sales of short-term investments | 177,293 | 160,532 |
| Purchase of short-term investments | (177,286) | — |
| Purchases of property and equipment | (245) | (422) |
| Net cash (used in) provided by investing activities | (238) | 160,110 |
| Cash flows from financing activities: | ||
| Proceeds received related to employee stock purchase plan and exercise of stock options | 3,797 | 2,019 |
| Proceeds from exercise of warrants (3) | — | 5,658 |
Item 1. Financial Statements.
FAQ
- What is Summit Therapeutics's capex?
- Summit Therapeutics (SMMT) reported capex of $245K in Q1 2026.
- How has Summit Therapeutics's capex changed year-over-year?
- Summit Therapeutics's capex decreased by 41.9% year-over-year, from $422K to $245K.
- What is the long-term trend for Summit Therapeutics's capex?
- Over 3 years (2021 to 2025), Summit Therapeutics's capex has grown at a 28.5% compound annual growth rate (CAGR), from $310K to $657K.
- What does capex mean?
- Cash spent on property, plant, and equipment — the primary measure of investment in productive capacity and infrastructure.
Ask your AI about Summit Therapeutics's capex.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude